Network Corporate Finance advised the Executive Board of Cryo-Save Group N.V., based in Zutphen, the Netherlands, on the preparation and execution of its listing on NYSE Euronext Amsterdam, as well as on the evaluation of strategic options.
Transaction
In order to strengthen its capital market profile and attract new investors, Cryo-Save Group’s shares, which were listed on the London Stock Exchange (AIM), were listed on NYSE Euronext Amsterdam. To this end, a 5:1 reverse share split was first carried out to consolidate the company’s existing shares at a nominal value of EUR 0.10 per share, thereby meeting the listing requirements of NYSE Euronext. At the same time, the prospectus was drawn up and subsequently approved by the competent supervisory authority, Stichting Autoriteit Financiële Markten (“AFM”). The shares were admitted to trading on NYSE Euronext Amsterdam on 22 October 2009.
Target Company
As Europe’s largest stem cell bank, the Cryo-Save Group specialises in the storage of stem cells from umbilical cord blood and umbilical cord tissue. Founded in 2000, the company pursues a growth strategy focused on international expansion and is now active in 38 countries. As of the end of 2009, it was managing more than 120,000 storage units.
Key Facts
| Transaction value: | EUR 61 Mio. |
| Sector: | Medizinische Dienstleistungen |
| Sales: | EUR 37 Mio. (2009e) |
| Employees: | approx. 220 |
| Date: | Oktober 2009 |
The role of Network Corporate Finance
Network Corporate Finance advised the client on the preparation and execution of the listing process and examined options for the company’s strategic development.
